ADI – Modified arginine deiminase as anti-tumor drug

Arginine deiminase (ADI) produces depletion of arginine and has been studied as a potential antitumor drug for the treatment of arginine-auxotrophic tumors such as hepato-cellular carcinoma (HCC) and malignant melanoma. These tumors that are sensitive to arginine depletion do not express a certain key enzyme in the synthesis of arginine from citrulline. Recent data showed that a pegylated form of ADI inhibits human melanomas and HCCs in vitro and in vivo. Furthermore, studies on human lymphatic leukemia cell lines confirmed ADI´s anti-angiogenic activity.

The main limitation for in vivo applications of numerous ADIs lies in their pH-dependant activity profile. ADI from Pseudomonas plecoglossicida (PpADI) for example has a pH optimum at 6.5. A shift from 6.5 to 7.5 (physiological conditions) results in an activity drop of approximately 80%. In order to shift the pH optimum, a directed-evolution protocol based on an adapted citrulline screening protocol in microtiter-plate format was developed and validated by the present invention. A proof of concept for ADI engineering resulted in an improved pH optimum and increased resistance under physiological and slightly alkaline conditions.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Novel catalyst for charge separation in photocatalytic water splitting

A research team led by Prof. JIANG Hailong, Prof. LUO Yi, and Prof. JIANG Jun from the University of Science and Technology of China (USTC) discovered a metal-organic framework (MOF)…

Finding a missing piece for neurodegenerative disease research

Research led by the University of Michigan has provided compelling  evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer’s, Parkinson’s and…

BESSY II: New procedure for better thermoplastics

Thermoplastic blends, produced by a new process, have better resilience. Now, experiments at the IRIS beamline show, why: nanocrystalline layers increase their performance. Bio-based thermoplastics are produced from renewable organic…